News for Zymeworks Inc. (ZYME)

Published at

Jul 17, 2025 1:19 PM

by gurufocus.com

positive

positive

Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025 | ZYME Stock News

Zymeworks (ZYME) will announce its Q2 2025 earnings on August 7, 2025, post-market close. The company will hold a conference call and webcast at 4:30 PM

ZYME

Read more →
Published at

Jul 17, 2025 1:00 PM

by gurufocus.com

positive

positive

Zymeworks Inc (ZYME) Announces Upcoming Financial Results and Investor Conference Participation | ZYME stock news

Summary Zymeworks Inc (ZYME), a clinical-stage biotechnology company focused on developing innovative biotherapeutics for challenging diseases, announced it wil

ZYME

Read more →
Published at

Jul 17, 2025 12:10 PM

by manilatimes.net

mixed

mixed

Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

Company to participate in investor conferences in July and August

JAZZ BGNEN.MX BGNE B1GN34.SA 6160.HK ZYME

Read more →
Published at

Jul 9, 2025 3:51 AM

by gurufocus.com

positive

positive

Redmile Group, LLC Increases Stake in Fate Therapeutics Inc

On July 2, 2025, Redmile Group, LLC (Trades, Portfolio) executed a significant transaction involving Fate Therapeutics Inc. The firm added 5,068,633 shares of F

ZYME FOLD.MX FOLD FATE 0HF9.L

Read more →
Published at

May 30, 2025 1:31 PM

by gurufocus.com

positive

positive

Zymeworks (ZYME) Receives China's Approval for Zanidatamab in Cancer Treatment | ZYME Stock News

Zymeworks (ZYME) has achieved a significant milestone as China's National Medical Products Administration granted conditional approval for zanidatamab. This app

ZYME

Read more →
Published at

May 30, 2025 1:16 PM

by gurufocus.com

positive

positive

Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer | ZYME Stock News

Zymeworks (ZYME) receives NMPA approval in China for zanidatamab, a first-of-its-kind bispecific antibody for HER2+ biliary tract cancer. The approval t

ZYME

Read more →
Published at

May 30, 2025 1:00 PM

by gurufocus.com

mixed

mixed

Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer

Zanidatamab is the first and only dual HER2-targeted bispecific antibody approved for HER2+ biliary tract cancer in China; conditional approval based on the res

BGNEN.MX BGNE B1GN34.SA 6160.HK ZYME

Read more →
Published at

May 30, 2025 3:32 AM

by gurufocus.com

positive

positive

Redmile Group, LLC's Strategic Acquisition in Atara Biotherapeutics Inc

On May 16, 2025, Redmile Group, LLC (Trades, Portfolio) executed a notable transaction involving Atara Biotherapeutics Inc. The firm added 263,506 shares of Ata

ZYME FOLD.MX FOLD ATRA 0HIY.L 0HF9.L

Read more →
Published at

May 22, 2025 11:19 PM

by manilatimes.net

mixed

mixed

Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences

**media[634760]**

JNJ JAZZ DJNJ3.BA DJNJ2.BA BGNEN.MX BGNE B1GN34.SA 6160.HK ZYME

Read more →
Published at

May 21, 2025 1:17 PM

by gurufocus.com

positive

positive

Zymeworks Announces Participation in Upcoming Investor Conferences | ZYME Stock News

Zymeworks Inc. (ZYME) announced its participation in three major investor conferences in June 2025. The company will hold one-on-one meetings and firesi

ZYME

Read more →
Published at

May 21, 2025 1:00 PM

by gurufocus.com

positive

positive

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, May 21, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. ( ZYME), a clinical-stage biotechnology company developing a diverse pipeline of

ZYME BGNEN.MX BGNE B1GN34.SA 6160.HK

Read more →
Published at

May 20, 2025 12:00 AM

by gurufocus.com

mixed

mixed

Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference

Company's first development candidate in autoimmune and inflammatory disease (AIID) demonstrates potent blockade of IL-4, IL-13, and IL-33 signaling pathways cr

BGNEN.MX BGNE B1GN34.SA 6160.HK ZYME

Read more →
Published at

May 19, 2025 11:46 PM

by gurufocus.com

positive

positive

Zymeworks (ZYME) Reveals Promising Preclinical Results for ZW1528 at Conference | ZYME Stock News

Zymeworks, trading under the ticker ZYME, has unveiled promising preclinical findings for its innovative bispecific molecule, ZW1528, which targets respiratory

ZYME

Read more →
Published at

May 9, 2025 9:45 AM

by gurufocus.com

positive

positive

Zymeworks Inc (ZYME) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Partnerships Propel Growth

Release Date: May 08, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Zymeworks Inc (ZY

ZYME JNJ DJNJ3.BA DJNJ2.BA

Read more →
Published at

May 9, 2025 7:22 AM

by gurufocus.com

neutral

neutral

Q1 2025 Zymeworks Inc Earnings Call Transcript

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NZYME.OQ - Zymeworks IncQ1 2025 Zymeworks Inc Earnings CallMay 08, 2025 / 08:30PM GMT =========

ZYME

Read more →
Published at

May 9, 2025 5:00 AM

by seekingalpha.com

positive

positive

Zymeworks Inc. (ZYME) Q1 2025 Earnings Call Transcript

Zymeworks Inc. (NASDAQ:ZYME) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ETCompany ParticipantsShrinal Inamdar - Senior Director, Investor...

ZYME

Read more →
Published at

May 9, 2025 4:58 AM

by seekingalpha.com

neutral

neutral

Zymeworks Inc. 2025 Q1 - Results - Earnings Call Presentation (NASDAQ:ZYME)

The following slide deck was published by Zymeworks Inc.

ZYME

Read more →
Published at

May 9, 2025 1:00 AM

by gurufocus.com

positive

positive

Zymeworks (ZYME) Surpasses Revenue Expectations in Q1 | ZYME Stock News

Zymeworks (ZYME) reported first-quarter revenue of $27.11 million, significantly exceeding the anticipated $20.65 million. This achievement highlights the compa

ZYME

Read more →
Published at

May 9, 2025 12:00 AM

by gurufocus.com

mixed

mixed

Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results

Six posters presented at the American Association for Cancer Research (AACR) annual meetingAppointment of Dr. Sabeen Mekan as Senior Vice President, Clinical De

BGNEN.MX BGNE B1GN34.SA 6160.HK ZYME

Read more →
Published at

May 8, 2025 11:50 PM

by zacks.com

positive

positive

Zymeworks Inc. (ZYME) Reports Q1 Loss, Tops Revenue Estimates

Zymeworks (ZYME) delivered earnings and revenue surprises of 33.33% and 57.36%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

ZYME

Read more →